These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 30345457

  • 1. Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
    Simpson EL, Paller AS, Boguniewicz M, Eichenfield LF, Feldman SR, Silverberg JI, Chamlin SL, Zane LT.
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):605-619. PubMed ID: 30345457
    [Abstract] [Full Text] [Related]

  • 2. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
    Ständer S, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Tom WL, Ports WC, Zielinski MA, Tallman AM, Tan H, Gerber RA.
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1742-1746. PubMed ID: 31132182
    [Abstract] [Full Text] [Related]

  • 3. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA, Hebert AA, Zaenglein AL, Silverberg JI, Tan H, Ports WC, Zielinski MA.
    Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
    [Abstract] [Full Text] [Related]

  • 4. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Sanders P, Vlahos B, Zang C, Lan J, Werth J.
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [Abstract] [Full Text] [Related]

  • 5. Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis.
    Stein Gold LF, Tom WL, Shi V, Sanders P, Zang C, Vlahos B, Cha A.
    Dermatitis; 2024 Jul; 35(1):84-91. PubMed ID: 38206678
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA.
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [Abstract] [Full Text] [Related]

  • 7. Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.
    Fowler J, Sugarman J, Sher L, Zang C, Werth JL, Myers DE, Graham D, Marfo AA, Takiya L.
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):951-960. PubMed ID: 36811773
    [Abstract] [Full Text] [Related]

  • 8. Relationship Among Treatment, Pruritus, Investigator's Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis.
    Simpson EL, Tom WL, Bushmakin AG, Cappelleri JC, Yosipovitch G, Ständer S, Luger T, Sanders P, Gerber RA, Myers DE.
    Dermatol Ther (Heidelb); 2021 Apr; 11(2):587-598. PubMed ID: 33751495
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
    Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C, Cork MJ.
    Allergy Asthma Proc; 2021 Sep 01; 42(5):425-431. PubMed ID: 34474712
    [Abstract] [Full Text] [Related]

  • 10. Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
    Simpson EL, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Ständer S, Tom WL, Ports WC, Zielinski MA, Tallman AM, Tan H, Gerber RA.
    Acta Derm Venereol; 2019 Jul 01; 99(9):756-761. PubMed ID: 30896779
    [Abstract] [Full Text] [Related]

  • 11. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
    Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Olivadoti M, Paller AS.
    Pediatr Dermatol; 2020 Nov 01; 37(6):1030-1037. PubMed ID: 32981097
    [Abstract] [Full Text] [Related]

  • 12. Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
    Silverberg JI, Tallman AM, Ports WC, Gerber RA, Tan H, Zielinski MA.
    Acta Derm Venereol; 2020 Jun 11; 100(13):adv00170. PubMed ID: 32318744
    [Abstract] [Full Text] [Related]

  • 13. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
    Eichenfield LF, Stein Gold LF, Lynde C, Guenther L, Greenberger S, Chu CY, Ghodsi Z, Vlahos B, Sanders P, Cha A, Canosa JM.
    Dermatol Ther (Heidelb); 2024 Apr 11; 14(4):875-892. PubMed ID: 38546803
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
    Ma L, Zhang L, Kobayashi M, Tao X, Qian Q, Cheng H, Liu S, Zhou Y, Chen Y, Zhang J.
    J Dermatol; 2023 Jul 11; 50(7):847-855. PubMed ID: 37154471
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
    Ma L, Tao X, Liu S, Cheng H, Fang R, Zhao Y, Cha A, Encinas GA, Zhou Y, Deng Y, Zhang J.
    Dermatol Ther (Heidelb); 2024 May 11; 14(5):1229-1243. PubMed ID: 38748345
    [Abstract] [Full Text] [Related]

  • 16. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
    Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, Ports WC, Purohit V, Takiya L, Werth JL, Zang C, Vlahos B, CARE 1 Investigators.
    Am J Clin Dermatol; 2020 Apr 11; 21(2):275-284. PubMed ID: 32212104
    [Abstract] [Full Text] [Related]

  • 17. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
    Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger TA.
    Dermatol Ther (Heidelb); 2021 Jun 11; 11(3):845-853. PubMed ID: 33728583
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
    Geng B, Hebert AA, Takiya L, Miller L, Werth JL, Zang C, Sanders P, Lebwohl MG.
    Dermatol Ther (Heidelb); 2021 Oct 11; 11(5):1667-1678. PubMed ID: 34379285
    [Abstract] [Full Text] [Related]

  • 19. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF, Gebauer K, Spelman L, Zane LT.
    J Drugs Dermatol; 2015 Oct 11; 14(10):1108-12. PubMed ID: 26461821
    [Abstract] [Full Text] [Related]

  • 20. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Ahmed A, Solman L, Williams HC.
    Br J Dermatol; 2018 Mar 11; 178(3):659-662. PubMed ID: 29205284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.